Edgewise Therapeutics Inc

NASDAQ EWTX

Download Data

Edgewise Therapeutics Inc Return on Tangible Equity (ROTE) 3 year CAGR for the year ending September 19, 2024

Edgewise Therapeutics Inc Return on Tangible Equity (ROTE) 3 year CAGR is NA for the year ending September 19, 2024. Return on tangible equity measures the profitability of a company relative to its tangible equity, which is shareholders' equity minus goodwill and intangible assets. It is calculated by dividing the net income by the tangible equity. This ratio indicates the return generated for each unit of tangible equity invested by the shareholders. A higher return on tangible equity suggests better profitability and value creation for the shareholders' tangible investment. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
NASDAQ: EWTX

Edgewise Therapeutics Inc

CEO Dr. Kevin Koch Ph.D.
IPO Date March 26, 2021
Location United States
Headquarters 3415 Colorado Avenue, Boulder, CO, United States, 80303
Employees 92
Sector Healthcare
Industry Biotechnology
Description

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

Similar companies

IPSC

Century Therapeutics Inc

NA

NA

CGEM

Cullinan Oncology LLC

NA

NA

ACET

Adicet Bio Inc

NA

NA

VOR

Vor Biopharma Inc

NA

NA

DSGN

Design Therapeutics Inc

NA

NA

ELYM

Eliem Therapeutics Inc

NA

NA

HOWL

Werewolf Therapeutics Inc

NA

NA

StockViz Staff

September 19, 2024

Any question? Send us an email